American Society of Clinical Oncology endorsement of the Cancer Care Ontario practice Guideline on Nonhormonal Therapy for Men with Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer

Ethan M. Basch, Mark R. Somerfield, Tomasz (Tom) Beer, Michael A. Carducci, Celestia S. Higano, Maha H A Hussain, Howard I. Scher

    Research output: Contribution to journalArticle

    74 Citations (Scopus)

    Abstract

    Purpose: In 2006, the American Society of Clinical Oncology (ASCO) Board of Directors (BOD) approved a policy and a set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods: The Cancer Care Ontario (CCO) Guideline on Non-Hormonal Therapy for Men With Metastatic Hormone-Refractory Prostate Cancer (HRPC) was reviewed for developmental rigor by methodologists. An ad hoc prostate cancer guideline review panel consisting of prostate cancer experts reviewed the content. Results: The ASCO ad hoc prostate cancer guideline review panel concurred that the recommendations are clear, thorough, based on the most relevant scientific evidence in this content area, and present options that will be acceptable to patients. The CCO guideline was subsequently endorsed by the ASCO BOD. The guideline recommends the use of docetaxel, prednisone/ hydrocortisone, and/or mitoxantrone in specific settings. Docetaxel-based chemotherapy is the only treatment that has demonstrated an overall survival benefit in men with HRPC. The use of estramustine in combination with other cytotoxic agents is not recommended. Continued gonadal androgen suppression and discontinuance of antiandrogens is recommended for men receiving chemotherapy. Conclusion: The review panel agreed with the recommendations as stated in the CCO guideline, with the following qualifications: two of the ASCO content reviewers noted the importance of considering other, nonhormonal therapies in this context that are beyond the scope of this guideline. The review panel notes that CCO has published separate guidelines on radiopharmaceuticals and bisphosphonates in men with castration-resistant (ie, hormone-refractory) metastatic prostate cancer.

    Original languageEnglish (US)
    Pages (from-to)5313-5318
    Number of pages6
    JournalJournal of Clinical Oncology
    Volume25
    Issue number33
    DOIs
    StatePublished - Nov 20 2007

    Fingerprint

    Castration
    Ontario
    Practice Guidelines
    Prostatic Neoplasms
    Hormones
    Guidelines
    docetaxel
    Medical Oncology
    Neoplasms
    Therapeutics
    Estramustine
    Drug Therapy
    Androgen Antagonists
    Mitoxantrone
    Radiopharmaceuticals
    Cytotoxins
    Diphosphonates
    Prednisone
    Androgens
    Hydrocortisone

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology

    Cite this

    American Society of Clinical Oncology endorsement of the Cancer Care Ontario practice Guideline on Nonhormonal Therapy for Men with Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer. / Basch, Ethan M.; Somerfield, Mark R.; Beer, Tomasz (Tom); Carducci, Michael A.; Higano, Celestia S.; Hussain, Maha H A; Scher, Howard I.

    In: Journal of Clinical Oncology, Vol. 25, No. 33, 20.11.2007, p. 5313-5318.

    Research output: Contribution to journalArticle

    Basch, Ethan M. ; Somerfield, Mark R. ; Beer, Tomasz (Tom) ; Carducci, Michael A. ; Higano, Celestia S. ; Hussain, Maha H A ; Scher, Howard I. / American Society of Clinical Oncology endorsement of the Cancer Care Ontario practice Guideline on Nonhormonal Therapy for Men with Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 33. pp. 5313-5318.
    @article{96e531bbafae43e6ad58ed3ecff8510f,
    title = "American Society of Clinical Oncology endorsement of the Cancer Care Ontario practice Guideline on Nonhormonal Therapy for Men with Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer",
    abstract = "Purpose: In 2006, the American Society of Clinical Oncology (ASCO) Board of Directors (BOD) approved a policy and a set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods: The Cancer Care Ontario (CCO) Guideline on Non-Hormonal Therapy for Men With Metastatic Hormone-Refractory Prostate Cancer (HRPC) was reviewed for developmental rigor by methodologists. An ad hoc prostate cancer guideline review panel consisting of prostate cancer experts reviewed the content. Results: The ASCO ad hoc prostate cancer guideline review panel concurred that the recommendations are clear, thorough, based on the most relevant scientific evidence in this content area, and present options that will be acceptable to patients. The CCO guideline was subsequently endorsed by the ASCO BOD. The guideline recommends the use of docetaxel, prednisone/ hydrocortisone, and/or mitoxantrone in specific settings. Docetaxel-based chemotherapy is the only treatment that has demonstrated an overall survival benefit in men with HRPC. The use of estramustine in combination with other cytotoxic agents is not recommended. Continued gonadal androgen suppression and discontinuance of antiandrogens is recommended for men receiving chemotherapy. Conclusion: The review panel agreed with the recommendations as stated in the CCO guideline, with the following qualifications: two of the ASCO content reviewers noted the importance of considering other, nonhormonal therapies in this context that are beyond the scope of this guideline. The review panel notes that CCO has published separate guidelines on radiopharmaceuticals and bisphosphonates in men with castration-resistant (ie, hormone-refractory) metastatic prostate cancer.",
    author = "Basch, {Ethan M.} and Somerfield, {Mark R.} and Beer, {Tomasz (Tom)} and Carducci, {Michael A.} and Higano, {Celestia S.} and Hussain, {Maha H A} and Scher, {Howard I.}",
    year = "2007",
    month = "11",
    day = "20",
    doi = "10.1200/JCO.2007.13.4536",
    language = "English (US)",
    volume = "25",
    pages = "5313--5318",
    journal = "Journal of Clinical Oncology",
    issn = "0732-183X",
    publisher = "American Society of Clinical Oncology",
    number = "33",

    }

    TY - JOUR

    T1 - American Society of Clinical Oncology endorsement of the Cancer Care Ontario practice Guideline on Nonhormonal Therapy for Men with Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer

    AU - Basch, Ethan M.

    AU - Somerfield, Mark R.

    AU - Beer, Tomasz (Tom)

    AU - Carducci, Michael A.

    AU - Higano, Celestia S.

    AU - Hussain, Maha H A

    AU - Scher, Howard I.

    PY - 2007/11/20

    Y1 - 2007/11/20

    N2 - Purpose: In 2006, the American Society of Clinical Oncology (ASCO) Board of Directors (BOD) approved a policy and a set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods: The Cancer Care Ontario (CCO) Guideline on Non-Hormonal Therapy for Men With Metastatic Hormone-Refractory Prostate Cancer (HRPC) was reviewed for developmental rigor by methodologists. An ad hoc prostate cancer guideline review panel consisting of prostate cancer experts reviewed the content. Results: The ASCO ad hoc prostate cancer guideline review panel concurred that the recommendations are clear, thorough, based on the most relevant scientific evidence in this content area, and present options that will be acceptable to patients. The CCO guideline was subsequently endorsed by the ASCO BOD. The guideline recommends the use of docetaxel, prednisone/ hydrocortisone, and/or mitoxantrone in specific settings. Docetaxel-based chemotherapy is the only treatment that has demonstrated an overall survival benefit in men with HRPC. The use of estramustine in combination with other cytotoxic agents is not recommended. Continued gonadal androgen suppression and discontinuance of antiandrogens is recommended for men receiving chemotherapy. Conclusion: The review panel agreed with the recommendations as stated in the CCO guideline, with the following qualifications: two of the ASCO content reviewers noted the importance of considering other, nonhormonal therapies in this context that are beyond the scope of this guideline. The review panel notes that CCO has published separate guidelines on radiopharmaceuticals and bisphosphonates in men with castration-resistant (ie, hormone-refractory) metastatic prostate cancer.

    AB - Purpose: In 2006, the American Society of Clinical Oncology (ASCO) Board of Directors (BOD) approved a policy and a set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods: The Cancer Care Ontario (CCO) Guideline on Non-Hormonal Therapy for Men With Metastatic Hormone-Refractory Prostate Cancer (HRPC) was reviewed for developmental rigor by methodologists. An ad hoc prostate cancer guideline review panel consisting of prostate cancer experts reviewed the content. Results: The ASCO ad hoc prostate cancer guideline review panel concurred that the recommendations are clear, thorough, based on the most relevant scientific evidence in this content area, and present options that will be acceptable to patients. The CCO guideline was subsequently endorsed by the ASCO BOD. The guideline recommends the use of docetaxel, prednisone/ hydrocortisone, and/or mitoxantrone in specific settings. Docetaxel-based chemotherapy is the only treatment that has demonstrated an overall survival benefit in men with HRPC. The use of estramustine in combination with other cytotoxic agents is not recommended. Continued gonadal androgen suppression and discontinuance of antiandrogens is recommended for men receiving chemotherapy. Conclusion: The review panel agreed with the recommendations as stated in the CCO guideline, with the following qualifications: two of the ASCO content reviewers noted the importance of considering other, nonhormonal therapies in this context that are beyond the scope of this guideline. The review panel notes that CCO has published separate guidelines on radiopharmaceuticals and bisphosphonates in men with castration-resistant (ie, hormone-refractory) metastatic prostate cancer.

    UR - http://www.scopus.com/inward/record.url?scp=36849038314&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=36849038314&partnerID=8YFLogxK

    U2 - 10.1200/JCO.2007.13.4536

    DO - 10.1200/JCO.2007.13.4536

    M3 - Article

    C2 - 17925542

    AN - SCOPUS:36849038314

    VL - 25

    SP - 5313

    EP - 5318

    JO - Journal of Clinical Oncology

    JF - Journal of Clinical Oncology

    SN - 0732-183X

    IS - 33

    ER -